Lack of BRAF mutation in primary uveal melanoma

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 7, 2003, Pages 2876-2878

  Cohen, Yoram ^a   Goldenberg Cohen, Nitza ^b   Parrella, Paola ^c   Chowers, Itay ^b   Merbs, Shannath L ^b   Pe'er, Jacob ^d   Sidransky, David ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Casa Sollievo della Sofferenza   (Italy)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; NUCLEOTIDE; RAF PROTEIN; THYMINE;

ARTICLE; BRAF GENE; CARCINOGENESIS; EXON; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; INCIDENCE; MISSENSE MUTATION; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION MAPPING; UVEA MELANOMA;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; MELANOMA; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-RAF; UVEAL NEOPLASMS;

EID: 0037562846     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-1329     Document Type: Article

References (25)

1. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet. 1996;347:1222-1225.
2. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43:2845-2851.
3. Iwamoto S, Burrows RC, Kalina RE, et al. Immunophenotypic differences between uveal and cutaneous melanomas. Arch Ophthalmol. 2002;120:466-470.
4. Gallagher RP, Elwood JM, Rootman J, et al. Risk factors for ocular melanoma: Western Canada Melanoma Study. J Natl Cancer Inst. 1985;74:775-778.
5. Soufir N, Bressac-de Paillerets B, Desjardins L, et al. Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes. Br J Cancer. 2000;82:818-822.
6. Tucker MA, Shields JA, Hartge P, Augsburger J, Hoover RN, Fraumeni JF Jr. Sunlight exposure as risk factor for intraocular malignant melanoma. N Engl J Med. 1985;313:789-792.
7. Rootman J, Gallagher RP. Color as a risk factor in iris melanoma. Am J Ophthalmol. 1984;98:558-561.
8. Guenel P, Laforest L, Cyr D, et al. Occupational risk factors, ultraviolet radiation, and ocular melanoma: a case-control study in France. Cancer Causes Control 2001;12:451-459.
9. Didolkar MS, Elias EG, Barber NA, Moore RH. Biologic behavior of ocular malignant melanoma and comparison with melanoma of the head and neck. Am J Surg. 1980;140:522-526.
10. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-1678.
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
12. Horsthemke B, Prescher G, Bornfeld N, Becher R. Loss of chromosome 3 alleles and multiplication of chromosome 8 alleles in uveal melanoma. Genes Chromosomes Cancer. 1992;4:217-221.
13. Parrella P, Sidransky D, Merbs SL. Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway. Cancer Res. 1999;59:3032-3037.
14. Scholes AG, Liloglou T, Maloney P, et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42:2472-2477.
15. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
16. Avruch J, Khokhlatchev A, Kyriakis JM, et al. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog Horm Res. 2001;56:127-155.
17. Mooy CM, Van der Helm MJ, Van der Kwast TH, De Jong PT, Ruiter DJ, Zwarthoff EC. No N-ras mutations in human uveal melanoma: the role of ultraviolet light revisited. Br J Cancer. 1991;64:411-413.
18. Soparker CN, O'Brien JM, Albert DM. Investigation of the role of the ras protooncogene point mutation in human uveal melanomas. Invest Ophthalmol Vis Sci. 1993;34:2203-2209.
19. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
20. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003;95:625-627.
21. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
22. Shors AR, Iwamoto S, Doody DR, Weiss NS. Relationship of uveal and cutaneous malignant melanoma in persons with multiple primary tumors. Int J Cancer. 2002;102:266-268.
23. Mooy CM, De Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol. 1996;41:215-228.
24. Marshall JF, Rutherford DC, Happerfield L, et al. Comparative analysis of integrins in vitro andi in vivo in uveal and cutaneous melanomas. Br J Cancer. 1998;79:522-529
25. Metzelaar-Blok JA, ter Huurne JA, Hurks HM, Keunen JE, Jager MJ, Gruis NA. Characterization of melanocortin-1 receptor gene variants in uveal melanoma patients. Invest Ophthalmol Vis Sci. 2001;42:1951-1954.